Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, reported unaudited financial results for the third quarter ended Dec. 31, 2025. The company highlighted continued progress across its HLP003 Phase 3 program for major depressive disorder (MDD) and HLP004 Phase 2 program for generalized anxiety disorder (GAD), along with a completed leadership transition and corporate rebranding.
Helus Pharma ended the quarter with $195.1 million in cash and reported a net loss of $42.7 million, as operating expenses increased to support advancing clinical activities. Management emphasized the company's strengthened balance sheet, expanding intellectual property portfolio, and upcoming clinical data milestones in 2026. The company's focus remains on developing proprietary novel serotonergic agonists (NSAs) designed to activate serotonin pathways believed to promote neuroplasticity.
HLP003, a proprietary NSA, is in Phase 3 clinical development for the adjunctive treatment of MDD and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. HLP004, also a proprietary NSA, is in Phase 2 development for GAD. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs. The company operates in Canada, the United States, the United Kingdom, and Ireland.
For more details, the full press release is available at https://ibn.fm/VigPf. Company updates can be found at www.helus.com, and the latest news and updates relating to HELP are available in the company's newsroom at https://ibn.fm/HELP.
The results underscore Helus Pharma's commitment to addressing the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, the company aims to improve the treatment landscape through the introduction of NSAs that provide durable improvements in mental health. Investors and stakeholders will be watching closely for upcoming clinical data readouts in 2026, which could significantly impact the company's valuation and the broader mental health treatment field.
